0A6I Stock Overview
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Soligenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$4.15 |
| 52 Week Low | US$0.37 |
| Beta | 1.85 |
| 1 Month Change | -32.86% |
| 3 Month Change | -36.12% |
| 1 Year Change | n/a |
| 3 Year Change | -98.22% |
| 5 Year Change | n/a |
| Change since IPO | -98.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A6I | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.6% | 3.8% | 1.2% |
| 1Y | n/a | -25.7% | 2.3% |
Return vs Industry: Insufficient data to determine how 0A6I performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0A6I performed against the UK Market.
Price Volatility
| 0A6I volatility | |
|---|---|
| 0A6I Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A6I's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A6I's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 14 | Christopher Schaber | www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.
Soligenix, Inc. Fundamentals Summary
| 0A6I fundamental statistics | |
|---|---|
| Market cap | US$5.55m |
| Earnings (TTM) | -US$6.14m |
| Revenue (TTM) | US$839.36k |
6.6x
P/S Ratio-0.9x
P/E RatioIs 0A6I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A6I income statement (TTM) | |
|---|---|
| Revenue | US$839.36k |
| Cost of Revenue | US$3.90m |
| Gross Profit | -US$3.06m |
| Other Expenses | US$3.08m |
| Earnings | -US$6.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | -365.15% |
| Net Profit Margin | -731.60% |
| Debt/Equity Ratio | 129.3% |
How did 0A6I perform over the long term?
See historical performance and comparison